Cancer Prevention Clinical Trials Network (CP-CTNet)

A medical professional shakes hands with a patient seated on a examination table.

The Cancer Prevention Clinical Trials Network (CP-CTNet) performs early phase clinical trials to assess the safety, tolerability, and cancer preventive potential of agents and interventions. By conducting prevention studies on people at increased risk due to inherited conditions, certain conditions that are associated with developing cancer, lifestyle-related risk or environmental exposure, the hope is to develop safe drugs and approaches that can decrease the risk of cancer.

These interventions target molecules or processes known to be important during carcinogenesis, such as cell proliferation (growth), apoptosis (programmed cell death), growth factor expression, oncogene expression, and immune response. The data from these trials help to develop further scientific insights into the mechanisms of cancer prevention, including the development of novel potential markers of response.

CP-CTNet trials are carried out across the United States and include phase 0 (micro-dosing), phase I (dose-finding), and phase II (preliminary efficacy) clinical. The overall goal of the network is to identify safe and effective preventive interventions that can move into large-scale clinical trials. See a list of trials.

Funding Opportunities and Application Information 2024

No matching Funding Opportunities were found.

View All Funding Opportunities

Grantee Details

PI Name Sort descending	PI Organization	Title	Grant Number	Program Official
Alexandrov, Ludmil B	University Of California, San Diego United States	Mapping immuno-genomic drivers of the head and neck precancer invasive-disease transition	5U01CA290479-03	Wendy Wang, Ph.D., M.Sc.
Allen, Peter J	Duke University United States	Biomarker validation for intraductal papillary mucinous neoplasms of the pancreas	5R01CA182076-08	Matthew Young, Ph.D.
Amuta, Ann Oyare	University Of Texas Arlington United States	Development of Tailored, Multilevel Cervical Cancer Interventions for Ethnically Diverse Black Women	1R15CA294297-01	Goli Samimi, Ph.D., M.P.H.
Anderson, Karen Sue	Arizona State University-Tempe Campus United States	Southwest EDRN Clinical Validation Center for Head and Neck Cancer	5U01CA281660-03	Wendy Wang, Ph.D., M.Sc.
Anderson, Karen Sue	Arizona State University-Tempe Campus United States	Southwest EDRN Clinical Validation Center for Head and Neck Cancer	5U01CA281660-03	Wendy Wang, Ph.D., M.Sc.
Anderson, Garnet L.	Fred Hutchinson Cancer Center United States	NCI Cancer Screening Research Network: Coordinating and Communication Center	3UG1CA286954-02S1	Elyse LeeVan, M.D., M.P.H.
Anderson, Daniel M	Healthpartners Institute United States	Metro-Minnesota Community Oncology Research Consortium (MMCORC)	3UG1CA189863-12S1	Vanessa A. White, M.P.H.
Anderson, Daniel M	Healthpartners Institute United States	Metro-Minnesota Community Oncology Research Consortium (MMCORC)	3UG1CA189863-12S1	Vanessa A. White, M.P.H.
Arnold, Corey Wells	University Of California Los Angeles United States	Computational Feature Profiling and Modeling for Prostate Cancer Detection and Risk Stratification	5R01CA279666-02	Indu Kohaar, Ph.D., M.Phil., M.Sc.
Atigadda, Venkatram Reddy	University Of Alabama At Birmingham United States	Development of Potent and non-toxic rexinoids to prevent non-melanoma skin cancer	5R01CA276683-03
Backman, Vadim	Northwestern University At Chicago United States	Optical hyperspectral nanoscale chromatin analysis for colon cancer risk-stratification	1R01CA289294-01A1	Claire Zhu, Ph.D.
Badu-Tawiah, Abraham	Ohio State University United States	Multiplexed Paper-Based Blood Test for Early-Stage Colorectal Cancer Screening	5R21CA270727-02	Claire Zhu, Ph.D.
Badve, Sunil S.	Emory University United States	Early prediction of lethal phenotypes in triple negative breast cancer using multiscale, multi-modality platforms	5R01CA281932-02	Wendy Wang, Ph.D., M.Sc.
Bae-Jump, Victoria Lin	Univ Of North Carolina Chapel Hill United States	Obesity-driven Metabolic and Molecular Biomarkers of Metformin Response in Endometrial Cancer	5R37CA226969-07	Goli Samimi, Ph.D., M.P.H.
Baghdadi, Tareq Al	Saint Joseph Mercy Health System United States	Michigan Cancer Research Consortium NCORP	3UG1CA189971-11S1	Vanessa A. White, M.P.H.

Program Guidelines for CP-CTNet

The Program Guidelines are available as a PDF.

Important Links

Clinical Trial Management Information can be found at CP-CTNet Instructions, Forms and Templates.

The data and biospecimens from several early phase prevention studies are available for request from the Cancer Data Access System (CDAS).

The link to the DMACC website can be found here: Data Management, Auditing and Coordinating Center (DMACC).

Downloadable files

Newsletters

The CP-CTNet Newsletter shares programmatic and research updates for the Cancer Prevention Clinical Trials Network (CP-CTNet). See the latest and all previous issues on the DMACC website.

I-SCORE Meetings

The Investigators-Site Coordinators Opportunity for Research Excellence (I-SCORE) meetings are held annually to stimulate information sharing and collaborations among DCP staff and Consortia members and to develop strategies to scientifically and operationally enhance DCP’s research program.

2025 I-SCORE will be held March 27-28, 2025 at NCI Shady Grove. For more information visit https://events.cancer.gov/dcp/iscore.

How Investigators Can Use CP-CTNet to Conduct Their Own Research

Accruing adequate numbers of study participants is a persistent challenge, especially for independent researchers. CP-CTNet, a cancer prevention research cooperative agreement-funded network, can provide a rich resource of individuals at risk for cancer who may be interested in participating in clinical trials.

An investigator interested in conducting a clinical trial with an agent ready for clinical testing can join a Lead Academic Organization to become an Affiliated Organization
An investigator who wishes to provide an agent for clinical study (but not to perform the clinical trial) can discuss with NCI/DCP if the agent is appropriate for study in CP-CTNet and then enter into a formal agreement with NCI/DCP to allow CP-CTNet to perform the trial
An investigator with a potential agent that requires more efficacy assessment or toxicology studies before moving to a clinical trial can be directed to the NCI/DCP PREVENT Cancer Preclinical Drug Development Program (PREVENT)

NCI/DCP has developed guidelines and processes to assist investigators in accessing CP-CTNet.

The CP-CTNet funding supports the Lead Academic Organizations (LAO) and the organizations affiliated with the LAO Sites. These funds are directed to the management and oversight of clinical trials, trial conduct, participant care as well as primary and major secondary endpoint analyses. Additional outside funds, such as those from institutional, foundation, or other grant programs may be utilized.

For more information, contact Goli Samimi, Ph.D., M.P.H., CP-CTNet Director, at goli.samimi@nih.gov.